The short version of peptide backbone fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-07-20. Anything still debated is marked as such rather than presented as settled.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Some childhood memories made lifelong impressions on him. As a boy, he carved a tiny mannequin into the end of the wooden ruler from his pencil case and placed it inside it. He added a stone, which he had painted into the upper and lower halves, and hid the case in the attic. Periodically, he would return to the mannequin, often bringing tiny sheets of paper with messages inscribed on them in his own secret language. He later reflected that this ceremonial act brought him a feeling of inner peace and security. Years later, he discovered similarities between his personal experience and the practices associated with totems in Indigenous cultures, such as the collection of soul-stones near Arlesheim or the tjurungas of Australia. He concluded that his intuitive ceremonial act was an unconscious ritual, which he had practiced in a way that was strikingly similar to those in distant locations which he, as a young boy, knew nothing about. His observations about symbols, archetypes, and the collective unconscious were inspired, in part, by these early experiences combined with his later research. At the age of 12, shortly before the end of his first year at the Humanistisches Gymnasium in Basel, Jung was pushed to the ground by another boy and hit his head, momentarily losing consciousness (he later recognised the incident was indirectly his fault). A thought then came to him—"Now you won't have to go to school anymore". From then on, whenever he walked to school or began homework, he fainted.
The Calvin cycle, also known as the dark reactions, is a series of biochemical reactions that fixes CO2 into G3P sugar molecules and uses the energy and electrons from the ATP and NADPH made in the light reactions. The Calvin cycle takes place in the stroma of the chloroplast. While named "the dark reactions", in most plants, they take place in the light, since the dark reactions are dependent on the products of the light reactions.
==== Nuclear power ==== There were three nuclear power plants in Schleswig-Holstein: Krümmel, Brunsbüttel, and Brokdorf. The last operating plant in Schleswig-Holstein, the Brokdorf-plant was shut down on new-years eve 2021. There is also a nuclear research center known "Helmholtz-Zentrum Geesthacht" (rebranded as Hereon) with 2 research reactors, located right next to the Krümmel plant. During the 1990s, ten more cases of leukemia among children than were expected were identified in Elbmarsch, near the Krümmel plant. Anti-nuclear activists believed it was due to the nuclear plant, which led to several investigations. The reported discovery of small spherical beads of nuclear material in the area led to further concern, as well as the presence of minute amounts of plutonium in the Elbe. The origins of the nuclear material were disputed, with one report determining them not to be that of the Krümmel plant. Another report claimed that they may have come from an undisclosed fire in 1986, however, this theory has been questioned as it would have required a substantial government cover-up. The Chernobyl disaster has also been suggested as a source, though it is considered unlikely. The probable source of the material, especially in the Elbe, is nuclear reprocessing plants in France. A 2010 report exonerated the nuclear power plants on the Elbe as the cause of contamination. Further doubt was cast on the nature of the supposed beads of nuclear material, with a Federal commission chastising the original commission that claimed to have discovered the beads.
Sources: en.wikipedia.org
In bioinformatics, a sequence alignment is a way of arranging the sequences of DNA, RNA, or protein to identify regions of similarity that may be due to functional, structural, or evolutionary relationships between the sequences. If two sequences in an alignment share a common ancestor, mismatches can be interpreted as point mutations and gaps as insertion or deletion mutations (indels) introduced in one or both lineages in the time since they diverged from one another. In sequence alignments of proteins, the degree of similarity between amino acids occupying a particular position in the sequence can be interpreted as a rough measure of how conserved a particular region or sequence motif is among lineages. The absence of substitutions, or the presence of only very conservative substitutions (that is, the substitution of amino acids whose side chains have similar biochemical properties) in a particular region of the sequence, suggest that this region has structural or functional importance. Although DNA and RNA nucleotide bases are more similar to each other than are amino acids, the conservation of base pairs can indicate a similar functional or structural role. Computational phylogenetics makes extensive use of sequence alignments in the construction and interpretation of phylogenetic trees, which are used to classify the evolutionary relationships between homologous genes represented in the genomes of divergent species. The degree to which sequences in a query set differ is qualitatively related to the sequences' evolutionary distance from one another.
The Bryant Park Corporation (BPC), formerly the Bryant Park Restoration Corporation (BPRC), manages the park. BPC also oversees the Bryant Park Management Corporation (BPMC), which was created to manage the Bryant Park business improvement district. Although Bryant Park is a public park, BPC accepts no public funds. It was initially supported by the Rockefeller Brothers Fund, but by the 21st century it received funding through tax assessments on surrounding property within the business improvement district, fees from concessionaires, and revenue from public events. As of 2024, the BPC raised about $29 million annually from sources such as rent payments and sponsorships. To obtain accurate data about park usage, BPC counts the number of patrons in Bryant Park at 1 p.m. and 6 p.m. every day.
Normal human hemoglobins are tetrameric proteins composed of two pairs of globin chains, each of which contains one alpha-like (α) globin and one beta-like (β) globin. Each globin chain is associated with an iron-containing heme moiety. Throughout life, the synthesis of the α and the β chains is balanced so that their ratio is relatively constant and there is no excess of either type. The specific α and β chains that are incorporated into Hb are highly regulated during development:
Sources: en.wikipedia.org
Subclass † Ellesmeroceratoidea Order † Plectronocerida (501 to 490 Ma) Order † Protactinocerida Order † Yanhecerida Order † Ellesmerocerida (500 to 470 Ma) Subclass † Endoceratoidea (485 to 430 Ma) Order † Endocerida (485 to 430 Ma) Order † Intejocerida (485 to 480 Ma) Subclass † Actinoceratoidea Order † Actinocerida (480 to 312 Ma) Subclass Nautiloidea (490.0 Ma- Rec) Order † Basslerocerida (490 to 480 Ma) Order † Tarphycerida (485 to 386 Ma) Order † Lituitida (485 to 480 Ma) Order † Discosorida (482 to 392 Ma) Order † Oncocerida (478.5 to 324 Ma) Order Nautilida (410.5 Ma-Rec) Subclass † Orthoceratoidea (482.5 to 211.5 Ma) Order † Orthocerida (482.5 to 211.5 Ma) Order † Ascocerida (478 to 412 Ma) Order † Dissidocerida (479 to 457.5 Ma) Order † Bajkalocerida Subclass † Bactritoidea (422 to 252 Ma) Subclass † Ammonoidea (410 to 66 Ma) Subclass Coleoidea (410.0 Ma-rec)
=== Defense towers === The porte d’Italie was guarded by two towers built to the east of the previous towers of the 4th century BC. The north tower or square tower, 10.50 m (34.4 ft) wide, is attached to the Wall of Crinas. Some internal blocks bear the marks of quarrymen or stonemasons. The south tower is also called the leaning tower, because its eastern facing has collapsed, the ground being formerly marshy. It was also square, 10.30 m (33.8 ft) wide. Only the eastern facing is preserved. It has two loopholes. These two towers, which rose to a height of 12 to 15 meters (39 to 49 ft), framed the porte d’Italie. A 22 m-long (72 ft) curtain wall connected the leaning tower to a rectangular tower (7.8 m × 8.4 m [26 ft × 28 ft]). This curtain wall has been rebuilt to give a better idea of this fortification.
African histoplasmosis Alternariosis Antibiotic candidiasis (iatrogenic candidiasis) Black piedra Candidal intertrigo Candidal onychomycosis Candidal paronychia Candidal vulvovaginitis Candidid Chromoblastomycosis (chromomycosis, cladosporiosis, Fonseca's disease, Pedroso's disease, phaeosporotrichosis, verrucous dermatitis) Chronic mucocutaneous candidiasis Coccidioidomycosis (California disease, desert rheumatism, San Joaquin Valley fever, valley fever) Congenital cutaneous candidiasis Cryptococcosis Dermatophytid Diaper candidiasis Disseminated coccidioidomycosis (coccidioidal granuloma) Distal subungual onychomycosis Entomophthoromycosis Erosio interdigitalis blastomycetica Favus Fungal folliculitis (majocchi granuloma) Fusariosis Geotrichosis Granuloma gluteale infantum Histoplasmosis (cave disease, Darling's disease, Ohio Valley disease, reticuloendotheliosis) Hyalohyphomycosis Kerion Lobomycosis (keloidal blastomycosis, lacaziosis, Lobo's disease) Mucormycosis Mycetoma (Madura foot, maduromycosis) North American blastomycosis (blastomycetic dermatitis, blastomycosis, Gilchrist's disease) Onychomycosis (dermatophytic onychomycosis, ringworm of the nail, tinea unguium) Oral candidiasis (thrush) Otomycosis Perianal candidiasis Perlèche (angular cheilitis) Phaeohyphomycosis Piedra (trichosporosis) Pityrosporum folliculitis Primary cutaneous aspergillosis Primary cutaneous coccidioidomycosis Primary cutaneous histoplasmosis Primary pulmonary coccidioidomycosis Primary pulmonary histoplasmosis Progressive disseminated histoplasmosis Proximal subungual onychomycosis Rhinosporidiosis South American blastomycosis (Brazilian blastomycosis, paracoccidioidal granuloma, paracoccidioidomycosis) Sporotrichosis (rose-gardener's disease) Systemic candidiasis Tinea barbae (barber's itch, ringworm of the beard, tinea sycosis) Tinea capitis (herpes tonsurans, ringworm of the hair, ringworm of the scalp, scalp ringworm, tinea tonsurans) Tinea corporis (ringworm, tinea circinata, tinea glabrosa) Tinea corporis gladiatorum Tinea cruris (crotch itch, eczema marginatum, gym itch, jock itch, ringworm of the groin) Tinea faciei Tinea imbricata (tokelau) Tinea incognito Tinea manuum Tinea nigra (superficial phaeohyphomycosis, tinea nigra palmaris et plantaris) Tinea pedis (athlete's foot, ringworm of the foot) Tinea versicolor (dermatomycosis furfuracea, pityriasis versicolor, tinea flava) Trichophyton mentagrophytes VII (TMVII) (an emerging sexually transmitted tinea of the genitals, buttocks, face, trunk, and extremities) White piedra White superficial onychomycosis Zygomycosis (phycomycosis)
Whereas MDA and psychedelics like psilocybin induce the head-twitch response in rodents, a behavioral proxy of psychedelic effects, findings on MDMA and the head-twitch response are mixed and conflicting. In addition, whereas MDA fully substitutes for psychedelics like LSD and DOM in rodent drug discrimination tests, MDMA does not do so, nor do psychedelics generally fully substitute for MDMA. Long-term repeated activation of serotonin 5-HT2B receptors by MDMA is thought to result in increased risk of organ complications such as valvular heart disease (VHD) and primary pulmonary hypertension (PPH). MDMA has been associated with serotonergic neurotoxicity. This may be due to formation of toxic MDMA metabolites and/or induction of simultaneous serotonin and dopamine release, with consequent uptake of dopamine into serotonergic neurons and breakdown into toxic species. Serotonin 5-HT2 receptor agonists or serotonergic psychedelics may potentiate the neurotoxicity of MDMA. MDMA is a racemic mixture of two enantiomers, (S)-MDMA and (R)-MDMA. (S)-MDMA is much more potent as an SNDRA in vitro and in producing MDMA-like subjective effects in humans than (R)-MDMA. By contrast, (R)-MDMA acts as a lower-potency serotonin–norepinephrine releasing agent (SNRA) with weak or negligible effects on dopamine. Relatedly, (R)-MDMA shows weak or negligible stimulant-like and rewarding effects in animals. Both (S)-MDMA and (R)-MDMA produce entactogen-type effects in animals and humans. In addition, both (S)-MDMA and (R)-MDMA are weak agonists of the serotonin 5-HT2 receptors.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.